Experimental
FOXO4-DRI
The prediction game
Call it: rising or fading?
Where does FOXO4-DRI stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: E (thin evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 4.1/10
FOXO4-DRI sits in Caution at 4.2 because it pairs one of the most elegant senolytic mechanisms and the most dramatic mouse result in the category with zero human evidence and grey-market-only sourcing. If you are fascinated by the science, the right move is to watch it, not inject it. The mechanism is real, the Baar 2017 data is real, and the structural follow-up in Bourgeois and Madl 2025 is real. What is missing is any human trial, any registered study, and any human safety data, while the mechanism itself, broad p53 modulation, is a genuine double-edged tool. The hype around this peptide far outruns its proof. If you want a senolytic with human evidence today, the better-supported path runs through fisetin and dasatinib plus quercetin. ✅ Best for: People who follow longevity science closely and want to track an unusually clever senolytic mechanism as it develops. Readers who understand that a striking mouse result is a reason to watch a field, not a reason to inject an unapproved peptide. Anyone comparing senolytic options who wants to see clearly why the human-evidenced choices outscore the famous one. Self-experimenters who, before considering any senolytic, will start with the oral compounds that actually have human data. Curious readers who want the honest version of the regrew fur in old mice story rather than the marketing version. ❌ Avoid if: You have active or suspected cancer, since deliberately modulating p53 and apoptosis with an uncharacterized peptide is exactly the wrong experiment. You expect human-proven anti-aging benefit, because there is none for this compound. You are uncomfortable injecting a grey-market research chemical with no guarantee of sterility, identity, or purity. You want a senolytic you can take orally with early human data behind it, in which case fisetin or dasatinib plus quercetin fit far better. You would read the dramatic mouse data as if it predicts human results, which is the exact error this report exists to prevent.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 4.9%
- BioHarmony Score
- 4.1/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.